Invention Grant
- Patent Title: NYESO TCR
-
Application No.: US16480987Application Date: 2019-01-28
-
Publication No.: US11267864B2Publication Date: 2022-03-08
- Inventor: Carina Wehner , Manon Weis
- Applicant: MEDIGENE IMMUNOTHERAPIES GMBH
- Applicant Address: DE Planegg-Martinsried
- Assignee: MEDIGENE IMMUNOTHERAPIES GMBH
- Current Assignee: MEDIGENE IMMUNOTHERAPIES GMBH
- Current Assignee Address: DE Planegg-Martinsried
- Agency: Clark & Elbing LLP
- Priority: LULU100715 20180226
- International Application: PCT/EP2019/051963 WO 20190128
- International Announcement: WO2019/162043 WO 20190829
- Main IPC: C07K14/725
- IPC: C07K14/725 ; C07K16/28

Abstract:
The present invention relates to an isolated T cell receptor (TCR) specific for NY-ESO-1/LAGE-1 and a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.
Public/Granted literature
- US20200148738A1 NYESO TCR Public/Granted day:2020-05-14
Information query